Ocular Adverse Events Linked to Chemotherapies Paclitaxel and Docetaxel
Drug Topics
SEPTEMBER 6, 2022
Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.
Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy
Hospital Pharmacy Europe
AUGUST 10, 2023
The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The number of serious related adverse events was low and similar between groups.
Chemotherapy 
97
97 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
Pharmacy Times
OCTOBER 25, 2023
Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both polymerase chain reaction and major pathologic response rates.
Chemotherapy 65
65 Chemotherapy 65
65 
First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC
Pharmacy Times
APRIL 18, 2025
A panelist discusses how waiting for molecular testing results before initiating treatment for nonsmall cell lung cancer (NSCLC) is crucial because patients with EGFR mutations can avoid chemotherapy and immunotherapy in favor of targeted oral agents like osimertinib, which offer survival benefits with minimal toxicity compared to traditional treatments, (..)
Chemotherapy 65
65 
Imfinzi with Neoadjuvant Chemotherapy Demonstrates Significant Benefit in Event-Free Survival Treating Resectable Non-Small Cell Lung Cancer
PharmExec
JULY 26, 2024
FDA’s Oncologic Drugs Advisory Committee acknowledged that Imfinzi met its primary endpoint of event-free survival in the treatment of resectable non-small cell lung cancer.
Chemotherapy 52
52 Chemotherapy 52
52 
Here’s a new data point for cancer patients to consider: ‘time toxicity’
STAT
APRIL 10, 2023
When Jeannette Cleland learned earlier this year that she could get chemotherapy at home, after dropping a particularly toxic medication, it seemed like good news. But then Cleland, a 44-year-old Minneapolis event planner who has stage 4 pancreatic cancer, did the math. Read the rest…
Chemotherapy 98
98 Chemotherapy 98
98 
Is prescribing anticancer drugs by body surface area still relevant?
Hospital Pharmacy Europe
JANUARY 23, 2025
The approach was adopted widely, particularly for cytotoxic chemotherapy agents, with the aim of standardising drug exposure and minimising toxicity. 5,6 Freireich et als work further validated this approach, showing that BSA correlated with drug efficacy and toxicity across several chemotherapy agents. 6 Gurney H.
Chemotherapy 64
64 
NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer
pharmaphorum
NOVEMBER 8, 2022
The National Institute for Health and Care Excellence (NICE) has recommended the use of KEYTRUDA (pembrolizumab) as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery, for adults with early TNBC, at high risk of recurrence, or locally advanced TNBC. After a median follow-up of 39.1
Chemotherapy 111
111 Chemotherapy 111
111 
Pembrolizumab Plus Chemotherapy Led to Pathological Complete Response in Patients with Breast Cancer
Pharmacy Times
JULY 31, 2023
The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
Chemotherapy 65
65 Chemotherapy 65
65 
New Study Evaluates Effects of Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer
Pharmacy Times
APRIL 18, 2023
Study authors determined that prevention or mitigation of myelotoxic events that destroy bone marrow can potentially lessen myelosuppression in patients with ES-SCLC.
Chemotherapy 65
65 Chemotherapy 65
65 
$5 billion bispecific antibody pharma collaboration
European Pharmaceutical Review
DECEMBER 7, 2022
In addition, A Phase III trial of Ivonescimab plus chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutated advanced non-squamous NSCLC that failed in prior epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) therapy is ongoing. percent and a median progression-free survival (mPFS) of 8.2
Chemotherapy 98
98 Chemotherapy 98
98 
Immunomedics wows ESMO with breast cancer data reveal
pharmaphorum
SEPTEMBER 21, 2020
Data from the phase 3 ASCENT study showed Trodelvy (sacituzumab govitecan) significantly extended overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies. in the chemotherapy arm.
Chemotherapy 91
91 
Kite releases pivotal CAR T therapy Phase III study results
European Pharmaceutical Review
MARCH 21, 2023
The landmark trial has demonstrated event-free survival (EFS), the primary endpoint, that is superior to historical SOC treatment. Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy.
Chemotherapy 145
145 Chemotherapy 145
145 
EC approves CAR T-Cell therapy for B-cell lymphoma
European Pharmaceutical Review
OCTOBER 18, 2022
The process starts with chemoimmunotherapy, and if a patient responds to and can tolerate further treatment, they move on to high-dose chemotherapy (HDT) followed by a stem cell transplant (ASCT). 3 cytokine release syndrome (CRS) and neurologic events were observed in 6 percent and 21 percent of patients, respectively. months vs 2.0
Chemotherapy 111
111 Chemotherapy 111
111 
Roche’s Tecentriq gets fourth European lung cancer indication
pharmaphorum
MAY 5, 2021
months in patients with high PD-L1 expression compared with standard chemotherapy. Grade 3–4 treatment-related adverse events were reported in 12.9% of people receiving chemotherapy. Approval is based on Roche’s phase 3 Impower110 study which showed Tecentriq monotherapy improved overall survival by 7.1
Chemotherapy 98
98 
US FDA grants approval for Orion-Bayer’s Nubeqa combo for prostate cancer
Pharmaceutical Technology
AUGUST 8, 2022
The latest approval is based on positive data from the multicentre, double-blind, randomised, placebo-controlled Phase III ARASENS clinical trial that analysed the safety and efficacy of oral darolutamide plus androgen deprivation therapy (ADT) and the chemotherapy docetaxel in mHSPC patients.
FDA 98
98 
FDA Approves Bristol Myers Squibb’s Opdivo in Combination with Chemotherapy for Resectable Non-Small Cell Lung Cancer
PharmExec
OCTOBER 4, 2024
Approval for Opdivo was based on results from the CheckMate-77T trial, which demonstrated that the combination significantly improved event-free survival and pathologic complete response in adults with resectable non-small cell lung cancer without EGFR or ALK rearrangements.
Chemotherapy 52
52 
Trial highlights potential next-gen biologic for lung cancer
European Pharmaceutical Review
OCTOBER 25, 2024
The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings.
Chemotherapy 97
97 
Novartis extends Kaiku digital patient monitoring partnership
pharmaphorum
AUGUST 31, 2022
In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.
Chemotherapy 116
116 
ESMO: TIL therapy improves on Yervoy in melanoma trial
pharmaphorum
SEPTEMBER 11, 2022
The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune responses to tumours, as well as immune-boosting cytokine interleukin-2, before the TILs are then reinfused into the patient intravenously.
Immunization 105
105 
Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer
pharmaphorum
FEBRUARY 11, 2021
The filing is based on findings of the innovaTV 204 phase 2 single-arm trial, in 101 patients with recurrent or metastatic disease previously treated with doublet chemotherapy and Roche’s Avastin (bevacizumab) if appropriate.
FDA 105
105 
Regulatory Submissions Filed for Opdivo Regimen in Resectable Non-Small Cell Lung Cancer
Pharmaceutical Commerce
FEBRUARY 7, 2024
Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.
Chemotherapy 52
52 Chemotherapy 52
52 
Bristol Myers Squibb Seeks Approval for Opdivo Regimen in Resectable Non-Small Cell Lung Cancer
PharmExec
FEBRUARY 7, 2024
Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful improvements in event-free survival in patients with resectable stage IIA to IIIB non-small cell lung cancer.
Chemotherapy 52
52 Chemotherapy 52
52 
Astellas/Seagen prepare full US filing of bladder cancer drug Padcev
pharmaphorum
FEBRUARY 15, 2021
The late stage data showed Padcev significantly improved overall survival compared with chemotherapy in a group of patients previously treated with platinum chemo and and a PD-1/L1 inhibitor. months in patients treated with Padcev compared with nine months in those treated with chemotherapy. months in the chemotherapy group.
Chemotherapy 69
69 
ASCO 2023: Keytruda becomes a new option in perioperative NSCLC
Pharmaceutical Technology
JUNE 4, 2023
Patients with resectable stage II, IIIA, and IIIB (T3-4N2) disease of both squamous and non-squamous histology were randomized to receive neoadjuvant Keytruda with platinum-based chemotherapy followed by adjuvant Keytruda, or placebo with platinum-based chemotherapy followed by placebo. At a median duration of follow-up of 25.2
Chemotherapy 75
75 
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
pharmaphorum
JUNE 11, 2021
Now, results from the ongoing TRANSFORM study show that Breyanzi was more effective than the standard second-line treatment – salvage therapy followed by high-dose chemotherapy and a stem cell transplant – at fending off disease recurrence.
Chemotherapy 83
83 
European Commission approves CAR T therapy for lymphoma
European Pharmaceutical Review
MAY 3, 2023
Breyanzi Phase III trial results In the Phase III TRANSFORM trial , Breyanzi more than quadrupled median event-free survival (EFS) compared to standard therapy with a median follow-up of 6.2 Standard care was determined as salvage immunochemotherapy followed by high-dose chemotherapy and hematopoietic stem cell transplant (HSCT).
Chemotherapy 98
98 Chemotherapy 98
98 
China accepts Junshi’s new drug application for NSCLC combo therapy
Pharmaceutical Technology
APRIL 12, 2023
The combined therapy includes toripalimab plus chemotherapy as peri-operative treatment and toripalimab monotherapy as consolidation therapy following adjuvant therapy. During the trial, patients with operable NSCLC were given toripalimab or a placebo along with platinum-based doublet chemotherapy as neoadjuvant and adjuvant therapy.
Chemotherapy 52
52 
Regenxbio expands MPS I gene therapy trial after first look at data
pharmaphorum
FEBRUARY 11, 2022
The first-look data from the phase 1/2 trial revealed no drug-related serious adverse events, positive effects on IDUA biomarkers in the CNS, as well as preliminary evidence of improved neurodevelopment. With RGX-111, Regenxbio hopes to offer a one-shot treatment that delivers a functional copy of the IDUA gene to cells in the CNS.
Chemotherapy 111
111 
Panbela Therapeutics and Johns Hopkins to expand ivospemin development
Pharmaceutical Technology
APRIL 4, 2023
The ORR and OS metrics surpassed the standard of care of gemcitabine plus nab-paclitaxel, and indicated potential complementary activity with the current standard chemotherapy regimen approved by the FDA.
Chemotherapy 59
59 
ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma
pharmaphorum
DECEMBER 13, 2021
In ZUMA-7, second-line treatment of relapsed or refractory LBCL patients with Yescarta extended median event-free survival (EFS) to 8.3 LBCL is the most common type of non-Hodgkin’s lymphoma (NHL) in adults, accounting for around a third of the 77,000 new cases diagnosed in the US.
Chemotherapy 98
98 
Tuoyi to transform treatment of recurrent/metastatic nasopharyngeal carcinoma
Pharmaceutical Technology
MARCH 6, 2023
Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).
Chemotherapy 52
52 
ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?
Pharmaceutical Technology
SEPTEMBER 13, 2022
Event-free survival (EFS) was the primary endpoint in this study, with the neoadjuvant arm reporting a two-year EFS of 72% in comparison to the 49% reported for the adjuvant arm. Overall survival (OS) data remains immature, with too few events for statistical analysis. MSI-H/dMMR CRC accounts for 10-15% of all CRC.
Immunization 69
69 
Bispecific antibody glofitamab to see NHS rollout for advanced lymphoma
Hospital Pharmacy Europe
OCTOBER 20, 2023
The most common adverse event was cytokine release syndrome (CRS) (63%). Adverse events of grade 3 or higher occurred in 62% of the patients, with grade 3 or higher CRS in 4% and grade 3 or higher neurologic events in 3%. Discontinuation of glofitamab due to adverse events occurred in 9% of the patients.
Chemotherapy 52
52 
Glofitamab provides fast and effective response in refractory mantle cell lymphoma
Hospital Pharmacy Europe
JANUARY 5, 2023
The first-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit or less intensive chemotherapy for less fit and transplant-ineligible individuals, although many eventually relapse with a progressive clinical course. Neurologic adverse events occurred in 15.4%
Chemotherapy 52
52 
2022 IDstewardship Year End Review
IDStewardship
DECEMBER 26, 2022
As someone who enjoys the simplicity of Sesame Street and the complexity of Antimicrobial Chemotherapy, this one was near and dear to my heart as well as a long time coming. Assuming there are no major life events for our team in 2023, we should be in for a year of steady growth. EDITOR’S CHOICE: BEST ARTICLE OF 2022.
Chemotherapy 130
130 
Enhancing collaboration to optimise medication therapy in older adults with cancer: a position paper from SOFOG-SFPO
Hospital Pharmacy Europe
DECEMBER 18, 2023
4,5 Polypharmacy – daily use of five or more drugs – is common in these patients and increases the risk of DRPs, which can result in adverse outcomes such as postoperative complications, chemotherapy toxicities and functional decline. 10,11 This can be due to side effects of chemotherapy or the addition of certain supportive care medications.
Chemotherapy 96
96 
Daiichi Sankyo receives Japan’s MHLW approval for VANFLYTA
Pharmaceutical Technology
MAY 26, 2023
The study also evaluated VANFLYTA in combination with standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation. It enrolled 539 adult patients aged 18 to 75 years from 193 study sites across Asia, North America, Europe, Oceania and South America.
Chemotherapy 52
52 Chemotherapy 52
52 
ASH: Servier’s Tibsovo poised for first-line used in AML
pharmaphorum
DECEMBER 13, 2021
The AGILE trial, which compared the combination of Tibsovo (ivosidenib) and Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) to Vidaza plus placebo as a first-line therapy for IDH1-positive AML, showed a three-fold improvement in overall survival. for the Tibsovo are and 14.9% for the control group. for the control group.
Labelling 52
52 
First-in-class MOv18 IgE antibody shows potential as safe and effective cancer therapy
Hospital Pharmacy Europe
JULY 27, 2023
MOv18 IgE safety A total of 26 patients were enrolled and, overall, MOv18 IgE was generally well tolerated with the majority of adverse events being low grade. The most common events were localised cutaneous toxicities including urticaria, pruritus and rash, which appeared to be dose-related.
Chemotherapy 52
52 
Leveraging innate cell engagers for lymphoma treatment
European Pharmaceutical Review
DECEMBER 28, 2023
As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. The majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile.
Immunization 84
84 
Novartis’ bid to extend Kymriah into earlier use hits a roadblock
pharmaphorum
AUGUST 24, 2021
In the phase 3 BELINDA trial, Kymriah (tisagenlecleucel) was unable to extend event-free survival wen used as a second-line therapy for aggressive B-cell lymphoma, dashing Novartis’ hopes of extending its current use in patients who have relapsed after receiving two lines of therapy.
Chemotherapy 52
52 
GSK bails on $4.2bn partnership with Merck on cancer drug
pharmaphorum
OCTOBER 1, 2021
Two months later, it missed the mark in another mid-stage study as a second-line monotherapy for biliary tract cancer (BTC), which was followed in August by a third failure as a first-line treatment alongside chemotherapy in locally advanced or metastatic BTC. billion takeover of Tesaro in 2019.
Chemotherapy 52
52 Chemotherapy 52
52 
EHA: Vertex, CRISPR build case for gene-editing drug
pharmaphorum
JUNE 12, 2022
CTX001 treatment has its limitations, however, not least that patient have to undergo myeloablative chemotherapy with a busulfan-based regimen followed by transplant with the CRISPR-modified cells back into the bone marrow. There have also ben no cases of cancer – a concern with bluebird’s gene therapy approach.
Chemotherapy 59
59 
Let's personalize your content